Advertisement

Organisation › Details
InflaRx (Group)
InflaRx is a biopharmaceutical company focusing on the development of new therapeutics controlling the inflammatory response based on its proprietary technology.. InflaRx has developed a pipeline of first-in-class antibodies directed against the terminal complement component C5a. While IFX-1 focuses on the acute care space, its product candidates, IFX-2 and IFX-3, are being developed in chronic inflammatory disease indications. InflaRx was founded in 2007 and is headquartered in Jena, Germany, with long standing research collaborations in the US and China. The team consists of renowned experts in complement research and clinical acute care. InflaRx is privately owned and financed by bm-t Beteiligungsmanagement Thüringen Gmbh, KfW banking group and various international family offices. *
![]() |
Start | 2007-01-01 established |
![]() |
Industry | anti-inflammatory drug |
Industry 2 | IFX-1 (InflaRx) | |
![]() |
Person | Riedemann, Niels C. (InflaRx 200803 Managing Director + founder) |
Person 2 | Christ, Arnd (Immatics 202010– CFO before InflaRx + Proteros + MediGene + NovImmune + Probiodrug + Hoechst) | |
![]() |
Region | Jena |
Country | Germany | |
Street | 2 Winzerlaer Str. | |
City | 07745 Jena | |
Address record changed: 2020-12-12 | ||
Basic data | Employees | n. a. |
Currency | EUR | |
Profit | -53,254,817 (2019-12-31) | |
Cash | 115,485,147 (2019-12-31) | |
* Document for �About Section�: | ||
Record changed: 2020-12-12 |
Advertisement

More documents for InflaRx (Group)
- [1] Immatics N.V.. (9/29/20). "Press Release: Immatics Appoints Arnd Christ as Chief Financial Officer". Tübingen & Houston, TX....
- [2] InflaRx N.V.. (9/17/20). "Press Release: InflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy Officer". Jena....
- [3] InflaRx N.V.. (3/31/20). "Press Release: InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx’s anti-C5a Technology". Jena....
- [4] InflaRx N.V.. (6/5/19). "Press Release: InflaRx Announces Top-Line SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa". Jena....
- [5] InflaRx N.V.. (2/14/19). "Press Release: Richard Brudnick to Join InflaRx Board of Directors". Jena....
- [6] InflaRx N.V.. (2/6/19). "Press Release: InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa". Jena....
- [7] InflaRx N.V.. (1/3/19). "Press Release: InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management". Jena & New York, NY....
- [8] InflaRx N.V.. (11/21/18). "Press Release: InflaRx N.V. Reports Third Quarter 2018 Financial & Operating Results". Jena....
- [9] InflaRx N.V.. (11/8/18). "Press Release: InflaRx Completes Enrollment in Phase IIb Clinical Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa". Jena....
- [10] InflaRx N.V.. (9/21/18). "Press Release: InflaRx N.V. Announces Appointment of Jens Holstein to Board of Directors". Jena....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top